Top

Published in:

01-10-2017 | Review

Capacity of gold nanoparticles in cancer radiotherapy

Authors: Nadeem M. S. Nagi, Yasir A. M. Khair, Ahmed M. E. Abdalla

Published in: Japanese Journal of Radiology | Issue 10/2017

Abstract

Radiotherapy is the ionizing radiation used for treatment of cancer and other diseases. Although radiotherapy is the major treatment for cancer, a lot of patients do not undergo radiation due to associated risks such as radiation pneumonitis, cardiovascular complications, development of secondary tumor, and lymphedema. However, the advantages of nanotechnology provide a unique potential to enhance radiotherapeutic performance, in particular by utilizing gold nanoparticles (Au NPs). In this review, we briefly describe the current direction of research towards the use of Au NPs for radiotherapeutic enhancement, combination, monitoring and in side effect reductions.

Perfézou M, Turner A, Merkoçi A. Cancer detection using nanoparticle-based sensors. Chem Soc Rev. 2012;41:2606–22.CrossRefPubMed

Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159:14–26.CrossRefPubMed

Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:S115–20.CrossRefPubMed

Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005;23:1934–40.CrossRefPubMed

Minami-Shimmyo Y, Ohe Y, Yamamoto S, Sumi M, Nokihara H, Horinouchi H, et al. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol. 2012;7:177–82.CrossRefPubMed

Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12:527–40.CrossRefPubMed

Hogle WP. The state of the art in radiation therapy. Semin Oncol Nurs. 2006;22:212–20.CrossRefPubMed

Halliwell B, Aruoma OI. DNA damage by oxygen-derived species: its mechanism and measurement in mammalian systems. FEBS Lett. 1991;281:9–19.CrossRefPubMed

Zhou Z, Song X, Wu A, Liu H, Wu H, Wu Q, et al. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy. Sci Rep. 2017;7:2748.CrossRefPubMedPubMedCentral

10.

Cheng YJ, Nie XY, Ji CC, Lin XX, Liu LJ, Chen XM, et al. Long-term cardiovascular risk after radiotherapy in women with breast cancer. J Am Heart Assoc. 2017;6:e005633.CrossRefPubMedPubMedCentral

11.

Mitra D, Catalano PJ, Cimbak N, Damato AL, Muto MG, Viswanathan AN. The risk of lymphedema after postoperative radiation therapy in endometrial cancer. J Gynecol Oncol. 2016;27:e4.CrossRefPubMed

12.

Kwatra D, Venugopal A, Anant S. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Transl Cancer Res. 2013;2:330–42.

13.

Jia F, Liu X, Li L, Mallapragada S, Narasimhan B, Wang Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J Control Release. 2013;172:1020–34.CrossRefPubMed

14.

Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Del Rev. 2012;64:206–12.CrossRef

15.

Hao R, Xing R, Xu Z, Hou Y, Gao S, Sun S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater. 2010;22:2729–42.CrossRefPubMed

16.

Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev. 2012;64:61–71.CrossRef

17.

Mesbahi A. A review on gold nanoparticles radiosensitization effect in radiation therapy of cancer. Rep Pract Oncol Radiother. 2010;15:176–80.CrossRefPubMedPubMedCentral

18.

Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul. 2007;1:37–51.CrossRefPubMed

19.

Norman A, Adams FH, Riley RF. Cytogenetic effects of contrast media and triiodobenzoic acid derivatives in human lymphocytes 1. Radiol. 1978;129:199–203.CrossRef

20.

Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale. 2012;4:4830–8.CrossRefPubMed

21.

Regulla D, Hieber L, Seidenbusch M. Physical and biological interface dose effects in tissue due to X-ray-induced release of secondary radiation from metallic gold surfaces. Radiat Res. 1998;150:92–100.CrossRefPubMed

22.

Herold ID, Stobbe CC, Iyer RV, Chapman JD. Gold microspheres: a selective technique for producing biologically effective dose enhancement. Int J Radiat Biol. 2000;76:1357–64.CrossRefPubMed

23.

Jeremic B, Aguerri AR, Filipovic N. Radiosensitization by gold nanoparticles. Clin Transl Oncol. 2013;15:593–601.CrossRefPubMed

24.

Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49:N309.CrossRefPubMed

25.

Zhang XD, Luo Z, Chen J, Song S, Yuan X, Shen X, et al. Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance. Sci Rep. 2015;5:8669.CrossRefPubMedPubMedCentral

26.

Zheng Y, Hunting DJ, Ayotte P, Sanche L. Radiosensitization of DNA by gold nanoparticles irradiated with high-energy electrons. Radiat Res. 2008;169:19–27.CrossRefPubMed

27.

Lawrence TS, Haffty BG, Harris JR. Milestones in the use of combined-modality radiation therapy and chemotherapy. J Clin Oncol. 2014;32:1173–9.CrossRefPubMed

28.

Xiong H, Zhou D, Qi Y, Zhang Z, Xie Z, Chen X, et al. Doxorubicin-loaded carborane-conjugated polymeric nanoparticles as delivery system for combination cancer therapy. Biomacromol. 2015;16:3980–8.CrossRef

29.

Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, et al. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;86:463–8.CrossRefPubMedPubMedCentral

30.

Kim K, Oh KS, Park DY, Lee JY, Lee BS, Kimb S, et al. Doxorubicin/gold-loaded core/shell nanoparticles for combination therapy to treat cancer through the enhanced tumor targeting. J Control Release. 2016;228:141–9.CrossRefPubMed

31.

Kaur J, Tikoo K. p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles. BBA Mol Cell Res. 2013;1833:1028–40.

32.

Brannon-Peppas L, Blanchette OJ. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2012;64:206–12.CrossRef

33.

Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010;596:467–88.CrossRefPubMedPubMedCentral

34.

Al-Dimassi S, Abou-Antoun T, El-Sibai M. Cancer cell resistance mechanisms: a mini review. Clin Transl Oncol. 2014;16:511–6.CrossRefPubMed

35.

Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–25.CrossRefPubMedPubMedCentral

36.

Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417–27.CrossRefPubMed

37.

Rochelle RA, Subinoy R, Oscar RM, Resham B, Vincent MR, Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011;7:580–7.CrossRef

38.

Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res. 2008;68:7570–8.CrossRefPubMedPubMedCentral

39.

Zhao J, Feng SS. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine. 2015;10:2199–228.CrossRefPubMed

40.

Hannah WC, Yulán H, João C, Margaret M, Pedro B, Jesus MF, et al. Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects. Nanomedicine. 2015;10:2513–25.CrossRef

41.

Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev. 2012;41:2256–82.CrossRefPubMed

42.

Jølck RI, Rydhög JS, Christensen AN, Hansen AE, Bruun LM, Schaarup-Jensen H, et al. Injectable colloidal gold for use in intrafractional 2D image-guided radiation therapy. Adv Healthc Mater. 2015;4:856–63.CrossRefPubMed

43.

Hainfeld JF, Smilowitz HM, O’Connor MJ, Dilmanian FA, Slatkin DN. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine. 2013;8:1601–9.CrossRefPubMed

44.

Pushpavanam K, Narayanan E, Chang J, Sapareto S, Rege K. A colorimetric plasmonic nanosensor for dosimetry of therapeutic levels of ionizing radiation. ACS Nano. 2015;9:11540–50.CrossRefPubMed

45.

Feng S, Zheng Z, Xu Y, Lin J, Chen G, Weng C, et al. A noninvasive cancer detection strategy based on gold nanoparticle surface-enhanced Raman spectroscopy of urinary modified nucleosides isolated by affinity chromatography. Biosens Bioelectron. 2017;91:616–22.CrossRefPubMed

46.

Win KY, Feng S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713–22.CrossRefPubMed

47.

Eblan MJ, Wang AZ. Improving chemoradiotherapy with nanoparticle therapeutics. Transl Cancer Res. 2013;2:320–9.PubMedPubMedCentral

48.

Barenholz YC. Doxil^®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–34.CrossRefPubMed

49.

Wang Y, Shim MS, Levinson NS, Sung HW, Xia Y. Stimuli-responsive materials for controlled release of theranostic agents. Adv Funct Mater. 2014;24:4206–20.CrossRefPubMedPubMedCentral

50.

Plank C, Scherer F, Schillinger U, Anton M, Bergemann C. Magnetofection: enhancing and targeting gene delivery by magnetic force. Eur Cell Mater. 2002;3:79–80.

51.

Julia K, Lina P, Anders H, Kristian B, Ernst W. Photochemically enhanced gene delivery of EGF receptor-targeted DNA polyplexes. J Drug Target. 2004;12:205–13.CrossRef

52.

Arkadi ZM, Ernst W. Temperature dependent gene expression induced by PNIPAM-based copolymers: potential of hyperthermia in gene transfer. Bioconjug Chem. 2006;17:766–72.CrossRef

53.

Marjan G, Hamishehkarc H. Redox and pH-responsive gold nanoparticles as a new platform for simultaneous triple anti-cancer drugs targeting. Int J Pharm. 2017;520:126–38.CrossRef

54.

Larson TA, Joshi PP, Sokolov K. Preventing protein adsorption and macrophage uptake of gold nanoparticles via a hydrophobic shield. ACS Nano. 2012;6:9182.CrossRefPubMedPubMedCentral

55.

Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9:1909–15.CrossRefPubMed

56.

Magzoub M, Jin S, Verkman A. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J. 2008;22:276–84.CrossRefPubMed

57.

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.CrossRefPubMed

Title: Capacity of gold nanoparticles in cancer radiotherapy
Authors: Nadeem M. S. Nagi
Yasir A. M. Khair
Ahmed M. E. Abdalla
Publication date: 01-10-2017
Publisher: Springer Japan
Published in: Japanese Journal of Radiology / Issue 10/2017
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-017-0671-6

At a glance: The STEP trials

Springer Medicine

Capacity of gold nanoparticles in cancer radiotherapy

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2017

Whole brain analyses of age-related microstructural changes quantified using different diffusional magnetic resonance imaging methods

Role of 18F-FDG PET/CT in patients affected by Langerhans cell histiocytosis

Methods for optimizing the display conditions of brain magnetic resonance images

MR imaging findings of vertebral involvement in Gorham–Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis

Renal dysfunction after abdominal or thoracic endovascular aortic aneurysm repair: incidence and risk factors

Single center experience with intralesional bleomycin sclerotherapy for lymphatic malformations